痛風治療薬の世界市場レポート 2025年

痛風治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.7％で50億3,000万米ドルに成長します。予測期間の成長は、ヘルスケア支出の増加、ドラッグデリバリーシステムの進歩、新規治療法の出現、慢性疾患管理に対する政府の取り組み、患者擁護・支援団体によるものです。予測期間の主な動向には、革新的な薬剤開発、新薬承認、個別化医療アプローチ、痛風管理向け遠隔医療サービス、尿酸降下療法の研究などが含まれます。

痛風の有病率の増加は、今後の痛風治療薬市場の拡大を牽引すると予測されます。痛風は関節の痛みや腫れを特徴とする炎症性関節炎の症状であり、痛風治療薬はこの痛み、腫れ、圧痛を治療し緩和することを目的としています。そのため、痛風の罹患率の増加は、痛風治療薬市場の売上高を増加させると予想されます。例えば、2024年6月、オーストラリアの政府機関であるAustralian Institute of Health and Welfareは、痛風が2022年の同国における573人の死亡の基礎原因として記録され、これは人口10万人当たり2.2人の死亡に相当すると報告しています。したがって、痛風の罹患率の増加は、痛風治療薬市場の成長を促進する重要な要因です。

肥満の有病率の増加は、今後数年間の痛風治療薬市場の拡大を促進すると予測されています。肥満は体脂肪の異常蓄積を特徴とし、痛風の発症および悪化の主要な危険因子と考えられています。肥満は痛風発作の頻度と重症度を高め、その管理に課題をもたらします。世界保健機関（WHO）の2022年3月の報告書によると、3億4,000万人の青少年、3,900万人の小児、6億5,000万人の成人を含む10億人以上が肥満の影響を受けています。肥満の有病率は増加の一途をたどっており、WHOの予測によれば、2025年までに1億6,700万人の大人と子どもが、体重過多または肥満による健康被害に直面することになります。したがって、肥満の増加は痛風治療薬市場の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の痛風治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の痛風治療薬市場：成長率分析
• 世界の痛風治療薬市場の実績：規模と成長, 2019-2024
• 世界の痛風治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の痛風治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の痛風治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• コルチコステロイド
• 利尿剤
• 世界の痛風治療薬市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• キサンチンオキシダーゼ阻害剤
• 尿酸尿治療薬
• 世界の痛風治療薬市場：病状別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性
• 慢性
• 世界の痛風治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の痛風治療薬市場、タイプ別サブセグメンテーション：非ステロイド性抗炎症薬（NSAID）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のNSAID
• 選択的 COX-2阻害剤
• 世界の痛風治療薬市場、タイプ別サブセグメンテーション：コルチコステロイド、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口コルチコステロイド
• 注射用コルチコステロイド
• 世界の痛風治療薬市場、タイプ別サブセグメンテーション：利尿薬、実績と予測, 2019-2024, 2024-2029F, 2034F
• チアジド系利尿薬
• ループ利尿薬

第7章 地域別・国別分析

• 世界の痛風治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の痛風治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 痛風治療薬市場：競合情勢
• 痛風治療薬市場：企業プロファイル
  • Sanofi-Aventis Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Sandoz
• Eisai Co. Ltd.
• Horizon Pharma Plc
• Jiangsu HengRui Medicine Co. Ltd.
• Hikma Pharmaceuticals plc
• Swedish Orphan Biovitrum AB
• JW Pharmaceutical Corp
• Lannett Company Inc
• BioCryst Pharmaceuticals Inc.
• Selecta Biosciences Inc.
• Rigel Pharmaceuticals Inc.
• CymaBay Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 痛風治療薬市場2029：新たな機会を提供する国
• 痛風治療薬市場2029：新たな機会を提供するセグメント
• 痛風治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gout therapeutics encompass medications designed to exert therapeutic effects in addressing the medical condition known as gout, or inflammatory arthritis, characterized by pain and swelling in joints. These therapeutics aim to treat and alleviate pain, swelling, and tenderness associated with gout.

The primary categories of gout therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) are medications employed to reduce inflammation, relieve pain, and lower elevated body temperatures. Treatment options encompass xanthine oxidase inhibitors and uricosuria medications tailored for various disease conditions, including both acute and chronic cases. These therapeutics find application across various end-users, including hospitals, specialty clinics, and others.

The gout therapeutics market research report is one of a series of new reports from The Business Research Company that provides gout therapeutics market statistics, including gout therapeutics industry global market size, regional shares, competitors with a gout therapeutics market share, detailed gout therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gout therapeutics industry. This gout therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gout therapeutics market size has grown rapidly in recent years. It will grow from $2.88 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increased prevalence of gout, changed lifestyle and dietary patterns, high blood pressure and diabetes prevalence, development of xanthine oxidase inhibitors, patient education initiatives

The gout therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.03 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising healthcare expenditure, advancements in drug delivery systems, emerging novel therapies, government initiatives for chronic disease management, patient advocacy and support groups. Major trends in the forecast period include innovative drug development, novel drug approvals, personalized medicine approaches, telehealth services for gout management, research in urate-lowering therapies.

The increasing prevalence of gout is anticipated to drive the expansion of the gout therapeutics market in the future. Gout is an inflammatory arthritis condition characterized by pain and swelling in the joints, and gout therapeutics aim to treat and alleviate this pain, swelling, and tenderness. Consequently, the rising incidence of gout is expected to enhance sales in the gout therapeutics market. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that gout was recorded as an underlying cause in 573 deaths in the country in 2022, representing 2.2 deaths per 100,000 people. Therefore, the growing incidence of gout is a significant factor driving the growth of the gout therapeutics market.

The growing prevalence of obesity is anticipated to fuel the expansion of the gout therapeutics market in the years to come. Obesity, characterized by an abnormal accumulation of body fat, is considered a major risk factor for the onset and exacerbation of gout. Obesity can intensify the frequency and severity of gout attacks, posing challenges in their management. According to the World Health Organization's March 2022 report, over 1 billion individuals globally, including 340 million adolescents, 39 million children, and 650 million adults, are affected by obesity. The prevalence of obesity continues to rise, with WHO projections indicating that by 2025, 167 million adults and children will face health consequences due to being overweight or obese. Therefore, the increasing prevalence of obesity stands as a driving force for the gout therapeutics market.

Product innovation is a prominent trend gaining traction in the gout therapeutics market, with major companies actively engaged in developing innovative treatments to maintain their competitive edge. An example of such innovation is seen in the August 2022 launch of SYNB2081 by Synlogic Inc., a US-based pharmaceutical company. SYNB2081, a synthetic biotic, represents a novel drug candidate designed for gout treatment, specifically aimed at lowering uric acid levels. This development is the outcome of a collaborative research effort between Synlogic and Ginkgo, a US-based biotech company.

Major companies in the gout therapeutics market are focusing on the development of innovative products, such as corticotropin. Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a peptide hormone secreted by the anterior pituitary gland in response to low cortisol levels in the blood. An illustration of this is seen in the January 2022 launch of Purified Cortrophin Gel (Repository Corticotropin Injection USP) 80 U/mL by ANI Pharmaceuticals, Inc., a US-based pharmaceutical company. This gel, an adrenocorticotropic hormone (ACTH), is marketed by ANI's newly established rare illness business unit and is used in the treatment of chronic autoimmune conditions such as acute exacerbations of multiple sclerosis (MS) and gouty arthritis (GA), as well as excess urine protein due to nephrotic syndrome.

In December 2022, Innovent Biologics, a China-based biopharmaceutical company, and LG Chem Life Sciences, a US-based pharmaceutical company, forged a strategic collaboration and license agreement for LG Chem's Tigulixostat, intended for the chronic management of hyperuricemia in patients with gout disease. This partnership grants Innovent exclusive rights to develop and commercialize Tigulixostat in China for $95.5 million, encompassing a $10 million upfront payment. LG Chem stands to receive milestones and tiered royalties based on net product sales in China. Tigulixostat, a novel xanthine oxidase inhibitor, targets the reduction of uric acid in purine metabolism, showcasing a therapeutic intervention for gout.

Major companies operating in the gout therapeutics market include Sanofi-Aventis, AstraZeneca plc, LG Chem Ltd., GlaxoSmithKline Plc, Takeda Pharmaceuticals Co. Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sandoz, Eisai Co. Ltd., Horizon Pharma Plc, Jiangsu HengRui Medicine Co. Ltd., Hikma Pharmaceuticals plc, Swedish Orphan Biovitrum AB, JW Pharmaceutical Corp, Lannett Company Inc, BioCryst Pharmaceuticals Inc., Selecta Biosciences Inc., Rigel Pharmaceuticals Inc., CymaBay Therapeutics Inc., GeneScience Pharmaceuticals Co. Ltd., Shanton Pharma

North America was the largest region in the gout therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gout therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gout therapeutics market consists of the sales of allopurinol, benzbromarone, febuxostat, probenecid, and pegloticase drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gout Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gout therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gout therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gout therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroid; Diuretics
• 2) By Treatment: Xanthine Oxidase Inhibitor; Uricosuria Medication
• 3) By Disease Condition: Acute; Chronic
• 4) By End-Users: Hospitals; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs; Selective COX-2 Inhibitors
• 2) By Corticosteroid: Oral Corticosteroids; Injectable Corticosteroids
• 3) By Diuretics: Thiazide Diuretics; Loop Diuretics
• Companies Mentioned: Sanofi-Aventis; AstraZeneca plc; LG Chem Ltd.; GlaxoSmithKline Plc; Takeda Pharmaceuticals Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gout Therapeutics Market Characteristics

3. Gout Therapeutics Market Trends And Strategies

4. Gout Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Gout Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gout Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gout Therapeutics Market Growth Rate Analysis
• 5.4. Global Gout Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gout Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gout Therapeutics Total Addressable Market (TAM)

6. Gout Therapeutics Market Segmentation

• 6.1. Global Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroid
• Diuretics
• 6.2. Global Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Xanthine Oxidase Inhibitor
• Uricosuria Medication
• 6.3. Global Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Chronic
• 6.4. Global Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.5. Global Gout Therapeutics Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Traditional NSAIDs
• Selective COX-2 Inhibitors
• 6.6. Global Gout Therapeutics Market, Sub-Segmentation Of Corticosteroid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Corticosteroids
• Injectable Corticosteroids
• 6.7. Global Gout Therapeutics Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thiazide Diuretics
• Loop Diuretics

7. Gout Therapeutics Market Regional And Country Analysis

• 7.1. Global Gout Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gout Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gout Therapeutics Market

• 8.1. Asia-Pacific Gout Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gout Therapeutics Market

• 9.1. China Gout Therapeutics Market Overview
• 9.2. China Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gout Therapeutics Market

• 10.1. India Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gout Therapeutics Market

• 11.1. Japan Gout Therapeutics Market Overview
• 11.2. Japan Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gout Therapeutics Market

• 12.1. Australia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gout Therapeutics Market

• 13.1. Indonesia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gout Therapeutics Market

• 14.1. South Korea Gout Therapeutics Market Overview
• 14.2. South Korea Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gout Therapeutics Market

• 15.1. Western Europe Gout Therapeutics Market Overview
• 15.2. Western Europe Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gout Therapeutics Market

• 16.1. UK Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gout Therapeutics Market

• 17.1. Germany Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gout Therapeutics Market

• 18.1. France Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gout Therapeutics Market

• 19.1. Italy Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gout Therapeutics Market

• 20.1. Spain Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gout Therapeutics Market

• 21.1. Eastern Europe Gout Therapeutics Market Overview
• 21.2. Eastern Europe Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gout Therapeutics Market

• 22.1. Russia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gout Therapeutics Market

• 23.1. North America Gout Therapeutics Market Overview
• 23.2. North America Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gout Therapeutics Market

• 24.1. USA Gout Therapeutics Market Overview
• 24.2. USA Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gout Therapeutics Market

• 25.1. Canada Gout Therapeutics Market Overview
• 25.2. Canada Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gout Therapeutics Market

• 26.1. South America Gout Therapeutics Market Overview
• 26.2. South America Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gout Therapeutics Market

• 27.1. Brazil Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gout Therapeutics Market

• 28.1. Middle East Gout Therapeutics Market Overview
• 28.2. Middle East Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gout Therapeutics Market

• 29.1. Africa Gout Therapeutics Market Overview
• 29.2. Africa Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gout Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Gout Therapeutics Market Competitive Landscape
• 30.2. Gout Therapeutics Market Company Profiles
  • 30.2.1. Sanofi-Aventis Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Gout Therapeutics Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. Sandoz
• 31.5. Eisai Co. Ltd.
• 31.6. Horizon Pharma Plc
• 31.7. Jiangsu HengRui Medicine Co. Ltd.
• 31.8. Hikma Pharmaceuticals plc
• 31.9. Swedish Orphan Biovitrum AB
• 31.10. JW Pharmaceutical Corp
• 31.11. Lannett Company Inc
• 31.12. BioCryst Pharmaceuticals Inc.
• 31.13. Selecta Biosciences Inc.
• 31.14. Rigel Pharmaceuticals Inc.
• 31.15. CymaBay Therapeutics Inc.

32. Global Gout Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gout Therapeutics Market

34. Recent Developments In The Gout Therapeutics Market

35. Gout Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Gout Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gout Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gout Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer